Journal Reviews

High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema

1 April 2017 | | Ocular Pathology and Oncology | Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor

The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...